Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Plasma Cell Disorders”

4,473 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 4,473 results

Testing effectiveness (Phase 2)WithdrawnNCT05170789
What this trial is testing

Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma

Who this might be right for
Relapsed Multiple MyelomaRefractory Multiple Myeloma
Tulane University School of Medicine
Large-scale testing (Phase 3)Study completedNCT01788020
What this trial is testing

Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia

Who this might be right for
Waldenström's Macroglobulinemia
University of Ulm 202
Testing effectiveness (Phase 2)Ended earlyNCT01023880
What this trial is testing

Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

Who this might be right for
Multiple Myeloma
Cephalon 62
Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Large-scale testing (Phase 3)Study completedNCT00546780
What this trial is testing

Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 31
Not applicableStudy completedNCT03602755
What this trial is testing

The First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain

Who this might be right for
Multiple Myeloma
Celgene 706
Not applicableStudy completedNCT05053685
What this trial is testing

Metanephrines in Obstructive Sleep Apnoea

Who this might be right for
PheochromocytomaObstructive Sleep ApneaCatecholamine; Secretion
Changi General Hospital 81
Early research (Phase 1)UnknownNCT04861480
What this trial is testing

Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Chongqing Precision Biotech Co., Ltd 18
Not applicableStudy completedNCT02984215
What this trial is testing

ACGH Impacts Survival in Plasma Cell PTLD

Who this might be right for
Post-transplantation Lymphoproliferative Disorders
Hospices Civils de Lyon 10
Early research (Phase 1)Active Not RecruitingNCT03283917
What this trial is testing

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Who this might be right for
Newly Diagnosed Primary AmyloidosisRecurrent Primary AmyloidosisRefractory Primary Amyloidosis
M.D. Anderson Cancer Center 21
Testing effectiveness (Phase 2)Study completedNCT00004889
What this trial is testing

Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

Who this might be right for
Lymphoma
Jonsson Comprehensive Cancer Center 8
Not applicableStudy completedNCT04999085
What this trial is testing

Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma

Who this might be right for
Multiple MyelomaMyelomaDisability Physical+1 more
UNC Lineberger Comprehensive Cancer Center 16
Early research (Phase 1)Looking for participantsNCT05652335
What this trial is testing

JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Who this might be right for
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC 180
Not applicableUnknownNCT00295997
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersKidney CancerLeukemia+4 more
University of California, San Francisco 35
Not applicableNot Yet RecruitingNCT06472479
What this trial is testing

LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University 66
Testing effectiveness (Phase 2)Study completedNCT02206425
What this trial is testing

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Oncotherapeutics 45
Testing effectiveness (Phase 2)Study completedNCT02213913
What this trial is testing

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Who this might be right for
Adult Grade III Lymphomatoid GranulomatosisB-cell Chronic Lymphocytic LeukemiaContiguous Stage II Adult Diffuse Large Cell Lymphoma+69 more
University of Chicago 55
Not applicableUnknownNCT05414162
What this trial is testing

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Who this might be right for
DLBCLMultiple MyelomaCytokine Release Syndrome+6 more
University Hospital, Bonn 60
Large-scale testing (Phase 3)Study completedNCT00657488
What this trial is testing

Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 400
Early research (Phase 1)Study completedNCT00443976
What this trial is testing

Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkins LymphomaUnspecified Adult Solid Tumor, Protocol Specific
NCIC Clinical Trials Group 35
Load More Results